Inviragen, Inc.
πΊπΈUnited States
- Country
- πΊπΈUnited States
- Ownership
- Private, Subsidiary
- Established
- 2003-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.inviragen.com
Safety and Immunogenicity Study of an Inactivated Vaccine Against Hand, Foot and Mouth Disease Caused by Enterovirus 71
Phase 1
Completed
- Conditions
- Hand, Foot and Mouth Disease
- Interventions
- Biological: INV21 Low DoseBiological: INV21 High DoseBiological: Placebo
- First Posted Date
- 2011-06-20
- Last Posted Date
- 2015-05-06
- Lead Sponsor
- Inviragen Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT01376479
- Locations
- πΈπ¬
Investigational Medicine Unit, National University Hospital, Singapore, Singapore
Safety and Immunogenicity Study to Assess TDV, a Live Attenuated Tetravalent Vaccine for Prevention of Dengue Fever
Phase 1
Completed
- Conditions
- Dengue Fever
- Interventions
- Biological: PlaceboBiological: TDV - Low DoseBiological: TDV - High Dose
- First Posted Date
- 2010-10-20
- Last Posted Date
- 2018-06-19
- Lead Sponsor
- Inviragen Inc.
- Target Recruit Count
- 96
- Registration Number
- NCT01224639
- Locations
- π¨π΄
Program For The Study and Control of Tropical Diseases, Medellin, Colombia
Β© Copyright 2025. All Rights Reserved by MedPath